15-Jun-2021

Cannovum AG enters cannabis market segment Dronabinol

DGAP-News: Cannovum AG / Key word(s): Product Launch
15.06.2021 / 10:02
The issuer is solely responsible for the content of this announcement.

Cannovum AG (stock markets Düsseldorf, München, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) is pleased to announce a strategic supply partnership for Dronabinol with a European medical cannabis supplier. Products are expected to be sold starting from August as part of the Cannovum brand range, with a signature supply contract initially running until the end of 2023.

Cannovum is expanding its medical cannabis portfolio by adding Dronabinol through its licensed subsidiary, Cannovum Health eG. Dronabinol is a synthesized cannabinoid first prescribable in 1998 and now primarily used in pain therapy. By adding this established medication to the product portfolio, Cannovum takes another step to ensure best possible patient care: only a full range of medical cannabis medication options grants doctors the opportunity to find the optimum individual treatment for each patient.

"The market for dronabinol has a volume of over €45 million in Germany alone. The inclusion in our portfolio under our own brand is an important milestone to provide patients in Germany and later Europe with a comprehensive range of medicinal cannabis. Cannabis extracts are to follow next," says Pia Marten, CEO of Cannovum AG.

In order to support doctors and pharmacists in finding the best possible treatment, Cannovum's pharmaceutical representatives have undergone intensive training on the full spectrum of Dronabinol with established medical professionals. Experience and expertise are key components in providing the best possible patient care, because every patient deserves the best therapy.

Contact:
Linda Rasch, IR & PR, Cannovum AG
Telefon +49 30 3982 163 62, linda.rasch@cannovum.com

About Cannovum AG:
Cannovum AG is the first German listed medical cannabis company. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com

15.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Cannovum AG
	Rheinsberger Str. 76/77
	10115 Berlin
	Germany
Phone:	+49 (0)30 3982 16360
E-mail:	ir@cannovum.com
Internet:	www.cannovum.com
ISIN:	DE000A2LQU21
WKN:	A2LQU2
Listed:	Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
EQS News ID:	1208107


End of News	DGAP News Service

Editor Details

Company:
- EQS Newsfeed
Website:
- EQS Newsfeed

Last Updated: 15-Jun-2021